Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $12.2300 (-4.82%) ($12.0000 - $13.0800) on Tue. Apr. 21, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.26% (three month average) | RSI | 65 | Latest Price | $12.2300(-4.82%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 3.3% a day on average for past five trading days. | Weekly Trend | TGTX advances 11.5% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(63%) ARKG(57%) ARKK(54%) IBB(54%) IBUY(52%) | Factors Impacting TGTX price | TGTX will decline at least -3.63% in a week (0% probabilities). VIXM(-33%) VXX(-31%) UUP(-15%) TLT(-1%) IYT(0%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -3.63% (StdDev 7.26%) | Hourly BBV | 0 () | Intraday Trend | -2.4% | | | |
|
5 Day Moving Average | $11.52(6.16%) | 10 Day Moving Average | $10.88(12.41%) | 20 Day Moving Average | $10.34(18.28%) | To recent high | -23.5% | To recent low | 71.3% | Market Cap | $1.549b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |